WO2004010973A3 - Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage - Google Patents
Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage Download PDFInfo
- Publication number
- WO2004010973A3 WO2004010973A3 PCT/US2003/024043 US0324043W WO2004010973A3 WO 2004010973 A3 WO2004010973 A3 WO 2004010973A3 US 0324043 W US0324043 W US 0324043W WO 2004010973 A3 WO2004010973 A3 WO 2004010973A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dosage form
- storage
- pharmaceutical dosage
- dissolution profile
- form capable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002494358A CA2494358A1 (en) | 2002-07-31 | 2003-07-31 | Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage |
JP2004524262A JP2005538994A (en) | 2002-07-31 | 2003-07-31 | Pharmaceutical dosage form capable of maintaining a stable dissolution profile in storage |
AU2003257982A AU2003257982A1 (en) | 2002-07-31 | 2003-07-31 | Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage |
BR0313149-1A BR0313149A (en) | 2002-07-31 | 2003-07-31 | Pharmaceutical dosage form capable of stable dissolution profile after storage |
MXPA05000862A MXPA05000862A (en) | 2002-07-31 | 2003-07-31 | Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage. |
EP03772160A EP1526845A2 (en) | 2002-07-31 | 2003-07-31 | Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39977602P | 2002-07-31 | 2002-07-31 | |
US39986202P | 2002-07-31 | 2002-07-31 | |
US39980802P | 2002-07-31 | 2002-07-31 | |
US39986302P | 2002-07-31 | 2002-07-31 | |
US60/399,776 | 2002-07-31 | ||
US60/399,808 | 2002-07-31 | ||
US60/399,863 | 2002-07-31 | ||
US60/399,862 | 2002-07-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004010973A2 WO2004010973A2 (en) | 2004-02-05 |
WO2004010973A3 true WO2004010973A3 (en) | 2004-08-05 |
Family
ID=31192378
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/024044 WO2004022032A2 (en) | 2002-07-31 | 2003-07-31 | Pharmaceutical dosage form comprising a sulfite compound |
PCT/US2003/024043 WO2004010973A2 (en) | 2002-07-31 | 2003-07-31 | Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage |
PCT/US2003/024045 WO2004010974A2 (en) | 2002-07-31 | 2003-07-31 | Gelatin capsule exhibiting reduced cross-linking |
PCT/US2003/024042 WO2004010972A2 (en) | 2002-07-31 | 2003-07-31 | Pellicle-resistant gelatin capsule |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/024044 WO2004022032A2 (en) | 2002-07-31 | 2003-07-31 | Pharmaceutical dosage form comprising a sulfite compound |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/024045 WO2004010974A2 (en) | 2002-07-31 | 2003-07-31 | Gelatin capsule exhibiting reduced cross-linking |
PCT/US2003/024042 WO2004010972A2 (en) | 2002-07-31 | 2003-07-31 | Pellicle-resistant gelatin capsule |
Country Status (7)
Country | Link |
---|---|
EP (4) | EP1526846A2 (en) |
JP (4) | JP2005538994A (en) |
AU (4) | AU2003257982A1 (en) |
BR (4) | BR0313149A (en) |
CA (4) | CA2494069A1 (en) |
MX (4) | MXPA05001166A (en) |
WO (4) | WO2004022032A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003240536B2 (en) | 2002-06-05 | 2007-11-15 | Ivax Pharmaceuticals, S.R.O. | Reduction of gelatin cross-linking |
WO2006089177A2 (en) | 2005-02-17 | 2006-08-24 | Synta Pharmaceuticals Corp. | Isoxazole combretastin derivatives for the treatment of disorders |
US7485323B2 (en) | 2005-05-31 | 2009-02-03 | Gelita Ag | Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions |
DK1906938T3 (en) * | 2005-07-26 | 2011-02-07 | Nicox Sa | Pharmaceutical formulation of nitric oxide derivatives of NSAIDs |
JP5503939B2 (en) * | 2009-10-16 | 2014-05-28 | 東洋カプセル株式会社 | Azelastine hydrochloride-containing capsule |
JP6887456B2 (en) | 2018-07-04 | 2021-06-16 | キャプシュゲル・ベルジウム・エヌ・ヴィ | A film-forming composition containing a surfactant or a surfactant and a salt as a whitening agent. |
US11364478B2 (en) * | 2019-05-22 | 2022-06-21 | Mezzimatic, LLC | Method of manufacturing throwable paintballs and paintballs made therefrom |
EP4257123A1 (en) * | 2020-12-01 | 2023-10-11 | Lg Chem, Ltd. | Stable oral formulation containing 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid |
CN113230241A (en) * | 2021-06-11 | 2021-08-10 | 北京畅盛医药科技有限公司 | Application of tris (hydroxymethyl) aminomethane salt in medicine for treating cardiovascular and cerebrovascular diseases |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2204401A1 (en) * | 1972-11-01 | 1974-05-24 | Meiji Seika Co | |
FR2617047A1 (en) * | 1987-06-23 | 1988-12-30 | Sanofi Sa | Gelatin composition which withstands tanning, capsules based on this composition and their pharmaceutical application, in particular to fenofibrate |
JPH0334921A (en) * | 1989-06-30 | 1991-02-14 | Teikoku Hormone Mfg Co Ltd | Gelatin capsule agent |
EP0679395A1 (en) * | 1994-04-26 | 1995-11-02 | Bayer S.p.A. | Pharmaceutical compositions containing a ketoprofen solution in a soft gelatine capsule and method to produce them |
EP0695544A1 (en) * | 1994-08-05 | 1996-02-07 | Shionogi & Co., Ltd. | Hard gelatin capsules resistant to denaturation and the production thereof |
WO2002056878A2 (en) * | 2001-01-18 | 2002-07-25 | Pharmacia Corporation | Pharmaceutical composition having reduced tendency for drug crystallization |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4349529A (en) * | 1980-04-14 | 1982-09-14 | E. R. Squibb & Sons, Inc. | Diagnostic and therapeutic capsules and method of producing |
US4590183A (en) * | 1985-04-22 | 1986-05-20 | Sterling Drug Inc. | Gastric cytoprotection with sodium thiosulfate in oral administration of aspirin |
LV10922B (en) * | 1994-03-15 | 1996-08-20 | Senju Pharma Co | Method for stabilizing pranoprofen and stable liquid preparation of pranprofen |
US5620704A (en) * | 1994-11-07 | 1997-04-15 | Warner-Lambert Company | Process for stabilizing gelatin products |
-
2003
- 2003-07-31 MX MXPA05001166A patent/MXPA05001166A/en unknown
- 2003-07-31 JP JP2004524262A patent/JP2005538994A/en not_active Withdrawn
- 2003-07-31 MX MXPA05000862A patent/MXPA05000862A/en not_active Application Discontinuation
- 2003-07-31 BR BR0313149-1A patent/BR0313149A/en not_active IP Right Cessation
- 2003-07-31 WO PCT/US2003/024044 patent/WO2004022032A2/en active Application Filing
- 2003-07-31 BR BR0312875-0A patent/BR0312875A/en not_active IP Right Cessation
- 2003-07-31 CA CA002494069A patent/CA2494069A1/en not_active Abandoned
- 2003-07-31 BR BR0313064-9A patent/BR0313064A/en not_active IP Right Cessation
- 2003-07-31 WO PCT/US2003/024043 patent/WO2004010973A2/en active Application Filing
- 2003-07-31 AU AU2003257982A patent/AU2003257982A1/en not_active Abandoned
- 2003-07-31 MX MXPA05001167A patent/MXPA05001167A/en unknown
- 2003-07-31 JP JP2004534259A patent/JP2006500389A/en not_active Withdrawn
- 2003-07-31 CA CA002494358A patent/CA2494358A1/en not_active Abandoned
- 2003-07-31 EP EP03772161A patent/EP1526846A2/en not_active Withdrawn
- 2003-07-31 WO PCT/US2003/024045 patent/WO2004010974A2/en active Application Filing
- 2003-07-31 EP EP03772160A patent/EP1526845A2/en not_active Withdrawn
- 2003-07-31 CA CA002493974A patent/CA2493974A1/en not_active Abandoned
- 2003-07-31 JP JP2004524261A patent/JP2005538993A/en not_active Withdrawn
- 2003-07-31 EP EP03772159A patent/EP1526844A2/en not_active Withdrawn
- 2003-07-31 AU AU2003257981A patent/AU2003257981A1/en not_active Abandoned
- 2003-07-31 AU AU2003257103A patent/AU2003257103A1/en not_active Abandoned
- 2003-07-31 EP EP03794452A patent/EP1526847A2/en not_active Withdrawn
- 2003-07-31 CA CA002493980A patent/CA2493980A1/en not_active Abandoned
- 2003-07-31 AU AU2003257102A patent/AU2003257102A1/en not_active Abandoned
- 2003-07-31 WO PCT/US2003/024042 patent/WO2004010972A2/en not_active Application Discontinuation
- 2003-07-31 BR BR0313150-5A patent/BR0313150A/en not_active IP Right Cessation
- 2003-07-31 JP JP2004524263A patent/JP2005538102A/en not_active Abandoned
- 2003-07-31 MX MXPA05001272A patent/MXPA05001272A/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2204401A1 (en) * | 1972-11-01 | 1974-05-24 | Meiji Seika Co | |
FR2617047A1 (en) * | 1987-06-23 | 1988-12-30 | Sanofi Sa | Gelatin composition which withstands tanning, capsules based on this composition and their pharmaceutical application, in particular to fenofibrate |
JPH0334921A (en) * | 1989-06-30 | 1991-02-14 | Teikoku Hormone Mfg Co Ltd | Gelatin capsule agent |
EP0679395A1 (en) * | 1994-04-26 | 1995-11-02 | Bayer S.p.A. | Pharmaceutical compositions containing a ketoprofen solution in a soft gelatine capsule and method to produce them |
EP0695544A1 (en) * | 1994-08-05 | 1996-02-07 | Shionogi & Co., Ltd. | Hard gelatin capsules resistant to denaturation and the production thereof |
WO2002056878A2 (en) * | 2001-01-18 | 2002-07-25 | Pharmacia Corporation | Pharmaceutical composition having reduced tendency for drug crystallization |
Non-Patent Citations (1)
Title |
---|
PATENT ABSTRACTS OF JAPAN vol. 0151, no. 63 (C - 0826) 24 April 1991 (1991-04-24) * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL245365A0 (en) | Modulators of atp-binding cassette transporters, pharmaceutical compositions containing the same and uses thereof | |
SI2395002T1 (en) | Pharmaceutical composition containing a heterocyclic modulator of atp-binding cassette transporters. | |
NO20042161L (en) | Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 | |
PL372998A1 (en) | Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them | |
IS4326A (en) | New storage granules and pharmaceutical compositions containing them | |
IL202190A0 (en) | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient | |
DE69928554D1 (en) | THERAPEUTIC FORMULATION CONTAINING DOSAGE FORM | |
WO2004112756A8 (en) | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient | |
IL164699A (en) | Derivatives of diketohydrazine compounds and pharmaceutical compositions and medicaments containing the compounds as the active ingredient | |
WO2005009381A3 (en) | Immediate-release formulation of acid-labile pharmaceutical compositions | |
HUP0203451A2 (en) | Pharmaceutical compositions of anti-tubercular drugs and process for their preparation | |
WO2001041737A3 (en) | Solid oral dosage form | |
EP1619180A4 (en) | CaSR ANTAGONIST | |
PL393385A1 (en) | Method for modification and habit recrystallization of drug substance, mycophenolate sodium crystals, the use thereof and pharmaceutical composition | |
GEP20043383B (en) | Cell Adhesion-Inhibiting Antiinflammatory and Immune-Suppressive Compounds | |
WO2006040779A3 (en) | Controlled release gastric floating matrix formulation containing imatinib | |
WO2004010973A3 (en) | Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage | |
ATE287264T1 (en) | ORAL MEDICINAL PRODUCTS CONTAINING BUPRENORPHINE | |
WO2005007137A3 (en) | Tablets containing ambroxol | |
EE200100104A (en) | A novel oral dosage form of a 5-HT4 agonist or antagonist | |
EA200700217A1 (en) | PHARMACEUTICAL COMPOSITION IN THE FORM OF TABLET FOR LOCATION IN THE STOMACH, CONTAINING AN ACTIVE SUBSTANCE | |
ATE491341T1 (en) | EDIBLE, DISSOLVING GELATIN STRIPS | |
WO2004062552A3 (en) | Pharmaceutical composition containing a nsaid and a benzimidazole derivative | |
WO2003045305A3 (en) | Acetaminophen compositions | |
EE200200032A (en) | Use of Interleukin-18 Inhibitors in the Formulation of Medicines for the Inhibition of Metastases and a Pharmaceutical Composition Containing such Inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/000862 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2494358 Country of ref document: CA Ref document number: 2003772160 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004524262 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003772160 Country of ref document: EP |